Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.
Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of pediatric laryngotracheobronchitis (croup) and results in close to 30,000 US hospitalizations each year. No effective vaccine is available. We examined murine PIV-1 (Sendai virus, SeV) as a live, xenotropic vaccine for the closely related human PIV-1 in a phase I, dose escalation study in healthy adults. Intranasal Sendai virus was uniformly well-tolerated and showed evidence of immunogenicity in three of nine vaccinees despite pre-existing, cross-reactive immunity presumably induced by previous exposure to human PIV-1. Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children.
Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA. karen.slobod@stjude.org
Karen S
KS
Slobod
Jerry L
JL
Shenep
Jorge
J
Luján-Zilbermann
Kim
K
Allison
Brita
B
Brown
Ruth Ann
RA
Scroggs
Allen
A
Portner
Chris
C
Coleclough
Julia L
JL
Hurwitz
D000281:Administration, Intranasal; D000328:Adult; D000818:Animals; D000937:Antigen-Antibody Reactions; D002642:Chick Embryo; D003429:Cross Reactions; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D009297:Nasal Mucosa / Q000276:immunology; D009500:Neutralization Tests; D022241:Parainfluenza Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D010222:Parainfluenza Virus 1, Human / Q000276:immunology*; D010253:Respirovirus Infections / Q000276:immunology* / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D022241:Parainfluenza Vaccines; D014613:Vaccines, Attenuated